Risk factors, mortality trends and cardiovasuclar diseases in people with Type 1 diabetes and controls: A Swedish observational cohort study

[1]  D. Maahs,et al.  Renal Complications and Duration of Diabetes: An International Comparison in Persons with Type 1 Diabetes , 2021, Diabetes Therapy.

[2]  I. Hirsch,et al.  The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2021, Diabetologia.

[3]  H. Wedel,et al.  Risk factors and incidence over time for lower extremity amputations in people with type 1 diabetes: an observational cohort study of 46,088 patients from the Swedish National Diabetes Registry , 2021, Diabetologia.

[4]  G. Filippatos,et al.  Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. , 2021, The New England journal of medicine.

[5]  A. Pehrsson,et al.  Evaluation of Reference Metrics for Continuous Glucose Monitoring in Persons Without Diabetes and Prediabetes , 2020, Journal of diabetes science and technology.

[6]  G. Filippatos,et al.  Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. , 2020, The New England journal of medicine.

[7]  M. Phillip,et al.  Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. , 2020, The lancet. Diabetes & endocrinology.

[8]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[9]  M. Phillip,et al.  Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT‐1 and ‐2 studies , 2020, Diabetes, obesity & metabolism.

[10]  C. Mathieu,et al.  2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2019, Diabetes Care.

[11]  10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.

[12]  Eyal Dassau,et al.  Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. , 2019, The New England journal of medicine.

[13]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[14]  S. Arnold,et al.  Cardiovascular Outcomes and Mortality in Type 2 Diabetes with Associated Cardio-Renal-Metabolic Comorbidities , 2018, Diabetes.

[15]  Merlin C. Thomas,et al.  Excess Mortality in Patients With Type 1 Diabetes Without Albuminuria—Separating the Contribution of Early and Late Risks , 2018, Diabetes Care.

[16]  L. Dimeglio,et al.  Type 1 Diabetes , 2019, Epidemiology of Diabetes.

[17]  Björn Eliasson,et al.  Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes , 2017, The New England journal of medicine.

[18]  Sofia Dahlqvist,et al.  Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial , 2017, JAMA.

[19]  T. Skrivarhaug,et al.  Long-term Mortality and End-Stage Renal Disease in a Type 1 Diabetes Population Diagnosed at Age 15–29 Years in Norway , 2016, Diabetes Care.

[20]  R. Vettor,et al.  SGLT2 Inhibitors and the Diabetic Kidney , 2016, Diabetes Care.

[21]  H. Wedel,et al.  Glycemic Control, Renal Complications, and Current Smoking in Relation to Excess Risk of Mortality in Persons With Type 1 Diabetes , 2016, Journal of diabetes science and technology.

[22]  Bo Carlberg,et al.  Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses , 2016 .

[23]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[24]  B. Zinman,et al.  Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. , 2015, JAMA.

[25]  S. Wild,et al.  Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. , 2015, JAMA.

[26]  A. Rosengren,et al.  Glycemic control and excess mortality in type 1 diabetes. , 2014, The New England journal of medicine.

[27]  L. Lipscombe,et al.  Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study , 2013, Diabetologia.

[28]  B. Carstensen,et al.  Time trends in mortality rates in type 1 diabetes from 2002 to 2011 , 2013, Diabetologia.

[29]  C. Forsblom,et al.  Time trends in mortality in patients with type 1 diabetes: nationwide population based cohort study , 2011, BMJ : British Medical Journal.

[30]  Ronald E. LaPorte,et al.  All-Cause Mortality Trends in a Large Population-Based Cohort With Long-Standing Childhood-Onset Type 1 Diabetes , 2010, Diabetes Care.

[31]  R. G. Miller,et al.  In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study , 2010, Diabetologia.

[32]  P. Nilsson,et al.  Glycemic Control and Cardiovascular Disease in 7,454 Patients With Type 1 Diabetes , 2010, Diabetes Care.

[33]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[34]  Merlin C. Thomas,et al.  The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes , 2009, Diabetes.

[35]  K. Borch-Johnsen,et al.  The Danish National Diabetes Register: trends in incidence, prevalence and mortality , 2008, Diabetologia.

[36]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[37]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.